3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Multiple Myeloma
9
Recurrence
5
Lymphoma, Large B-Cell, Diffuse
3
Leukemia, Myeloid, Acute
3
Sarcoma
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vascular Neoplasms
1
Triple Negative Breast Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumor Malignancy
1
Smooth Muscle Tumor
1
Sarcoma, Clear Cell
1
Recurrent Squamous Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms, Adipose Tissue
1
Neoplasm Metastasis
1
Myoepithelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Interventions
Cisplatin
3
Amifostine
3
Radiotherapy
2
Paclitaxel
2
sodium thiosulfate
1
selinexor
1
Trastuzumab
1
Topotecan
1
Pharmaceutical Preparations
1
Nivolumab
1
Methotrexate
1
Imatinib Mesylate
1
Filgrastim
1
Etoposide
1
Drug Combinations
1
Doxorubicin
1
Docetaxel
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Drug-Related Side Effects and Adverse Reactions
×
selinexor
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled